Exchange: NASDAQ·Updated 07:30 PM EDT

ANIP News

News
all
press releases
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?
ANI Pharmaceuticals' low valuation and strong 2026 growth outlook face a key test as Cortrophin execution risk rises.
Zacks
More News
ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth
Cortrophin guidance cuts put more pressure on ANI Pharmaceuticals' second-half execution as the drug must deliver a sharper growth ramp.
Zacks
ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut
ANI Pharmaceuticals tops Q2 earnings and sales estimates, but shares fall as the company cuts its 2026 Cortrophin Gel revenue outlook.
Zacks
These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results
ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported strong Q2 earnings, affirmed FY2026 guidance, and saw changes in price targets by analysts.read more...
Benzinga
Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks
ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimates
ANI (ANIP) delivered earnings and revenue surprises of +9.95% and +1.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
ANI Pharmaceuticals, Inc. Profit Climbs In Q2
(RTTNews) - ANI Pharmaceuticals, Inc. (ANIP) revealed earnings for its second quarter that Increases, from the same period last year...
Nasdaq News: Markets
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates
Denali Therapeutics (DNLI) delivered earnings and revenue surprises of +5.56% and +143.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Lags Revenue Estimates
ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of -5.88% and -46.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline
Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks

Advertisement|Remove ads.